Vertex: More Appealing At A Lower Price, But Don't Rush In (Rating Upgrade)
Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...
Vertex Pharmaceuticals says VX-264 study did not meet primary endpoint
Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...
Vertex to Cease Clinical Trials on Diabetes Treatment
Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.
Zacks Investment Research on MSN22h
Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...